Brought to you by 
P&U licenses diabetes drug from Japan Tobacco
13 Jul 1999
Executive Summary
Japan Tobacco has licensed Pharmacia & Upjohn development and marketing rights, worldwide outside Japan and Korea, to its JTT-501 insulin sensitizer, currently in Phase II for treating Type II (adult onset) diabetes.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
P&U licenses diabetes drug from Japan Tobacco
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice